Cancer susceptibility gene mutations fall into two genFirst, both BRCA1 and BRCA2 work to preserve chromoeral classes (Kinzler and Vogelstein, 1997). Genes whose some structure, yet the precise nature of their contribumutation or altered expression relieves normal controls tion has proven difficult to define, because both proteins on cell division, death, or lifespan, promoting the outhave been implicated in a multitude of different processes growth of cancer cells, have been termed "gatekeepincluding DNA repair and recombination, cell cycle control, ers." Those whose disruption causes genome instability, and transcription. Second, the similarities between the increasing the frequency of alterations in gatekeeper phenotypes induced by disruption of BRCA1 or BRCA2 genes, work instead as "caretakers." and their claimed cohabitation in certain macromolecu-A starting point from which to unravel the functions lar complexes has prompted speculation that they work of BRCA1 and BRCA2 relevant to cancer predisposition together in common cellular pathways.
tions. In the discussion that follows, it will be proposed cleotide alterations are tolerated at the sites of rejointhat the major role of BRCA2 in DSB repair is through ing, or by recombination between homologous DNA secontrol of the RAD51 recombinase, while BRCA1 perquences (HR), error-free when the exchange is between forms a distinct and more general function as a link identical sister chromatids (or homologous chromosomes).
between the sensing/signaling and effector components A third mechanism, single-strand annealing (SSA), is also of the mammalian response to DNA damage, helping to initiated by homologous pairing, except that-unlike ensure that the ensuing response is appropriate to the HR-the homology is between short stretches of singleinitiating lesion. stranded DNA (ssDNA) at staggered DSBs, and pairing precedes religation, not strand exchange. SSA is error-BRCA2 Controls the RAD51 Recombinase prone because sequence information can be lost or re-BRCA2 binds directly with RAD51 (Sharan et There is now good evidence that BRCA1 is phosphorysponse to different DNA damaging agents, will affect in a specific way its interaction with different effector lated by the mammalian homologs of at least three kinases in this group and that the modifications contribute pathways. Direct experimental evidence to support this idea is currently limited, and available information sugto its function. The kinases include ATM (the RAD3p/ TEL1p homolog mutated in the human disease ataxia gests it will not be easy to come by. The tumor suppressor p53 (like BRCA1, a protein to which a long list of telangiectasia), the ATM-related MEC1p homolog ATR, and CHK2, homologous to CDS1p/RAD53p. Interestfunctions in DNA damage responses has been ascribed) is a case in point. p53, too, undergoes complex patterns ingly, patients with ataxia telangiectasia are susceptible to cancer, and cells deficient in ATM or ATR exhibit a of phosphorylation by checkpoint kinases that are predicted to alter downstream functions; but many years progressive impediment to cell proliferation and spontaneous chromosomal instability, as do BRCA-deficient after its description, the biological meaning of p53 phosphorylation is yet to be precisely specified. cells, hinting that the biological functions of these kinases may in part be mediated through BRCA phosphorThe likely complexities of the role played by BRCA1 in connecting DNA damage-sensing and response ylation. Not all cancers from BRCA mutation carriers contain sistent with the arguments put forward here that the BRCA proteins perform distinct functions in overlapping mutant p53, however, suggesting that there will be alternative paths to transformation in this setting. Indeed, biological processes. Further characterization of these differences at the molecular level will undoubtedly assist the identity of the checkpoints that arrest growth in BRCA-deficient cells is not fully clear. Besides checkunderstanding of BRCA protein function, besides tumorigenesis. Furthermore, the inference that at least some points governed by p53, there is in vitro evidence that the inactivation of mitotic checkpoints, such as the spinof the molecular changes within each group will be stereotyped holds out hope for improvements in diagnosis dle assembly checkpoint mediated in mammals by a protein complex containing the Bub1 and BubR1 kiand treatment. nases, is sufficient to overcome growth arrest and promote the transformation of BRCA2-deficient murine can be effectively translated into advances in the preGarcia-Higuera, I., Taniguchi 
